Physician profile
Ryan J Burris
NPI 1710305826
$42,808.24
in general payments reported to CMS, 2019-2025
27 companies · $933 in 2025
The $933 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.22 · 2020: $23K · 2021: $16K · 2022: $1,983 · 2023: $382 · 2024: $698 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.32 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $12,514.23 | 2020 | |
| Boston Scientific Corporation | $10,825.03 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, Ingevity+, General - Therapies |
| Medtronic, INC. | $9,539.05 | 2021-2025 | Micra, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $6,062.34 | 2019-2023 | Jot Dx |
| Biotronik INC. | $1,114.33 | 2021-2025 | |
| Biosense Webster, INC. | $908.87 | 2020-2025 | Carto 3, Soundstar |
| Medical Device Business Services, INC. | $375.00 | 2024 | Carto 3 |
| Cardiva Medical, INC. | $286.78 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Cvrx, INC. | $213.20 | 2021 | |
| Kestra Medical Technology Services, INC. | $209.01 | 2022-2025 | Assure Wcd |
| Amgen INC. | $119.43 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $113.62 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $103.74 | 2023-2025 | |
| Atricure, INC. | $97.04 | 2021-2023 | |
| Cardiofocus, INC. | $53.17 | 2023 | Heartlight System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.86 | 2023-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $33.27 | 2023 | |
| Terumo Medical Corporation | $29.67 | 2024 | Azur Cx Detachable |
| Astrazeneca Pharmaceuticals LP | $27.34 | 2021 | |
| Inspire Medical Systems, INC. | $24.90 | 2025 | Inspire |
| Novo Nordisk INC | $22.49 | 2025 | Wegovy |
| Tactile Systems Technology INC | $21.81 | 2024 | Entre Plus, Flexitouch Plus |
| Cardiovascular Systems INC. | $17.96 | 2019 | |
| Bsn Medical INC | $16.25 | 2025 | |
| Merck Sharp & Dohme LLC | $16.24 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.91 | 2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Burris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.